- Fellowship - University of Cincinnati (2008-2011), Hematology Oncology
- Residency - University of Cincinnati College of Medicine (2005-2008), Internal Medicine
- Medical School - Aga Khan Univ, Pakistan (1998-2003)
Muhammad Beg, M.D.
- Dedman Family Scholar in Clinical Care
- Internal Medicine - Hematology/Oncology
- Medical Treatment of Pancreatic Cancer
- Pancreatic Cancer
Muhammad Shaalan Beg, M.D., has a lot of irons in the fire at UT Southwestern Medical Center. And his patients are the driving force behind everything he does here.
He is Director for Gastrointestinal (GI) Medical Oncology at UT Southwestern. As a medical oncologist, Dr. Beg treats patients with cancer of the pancreas, bile duct, and liver. He is an Associate Professor of Hematology and Medical Oncology and is Medical Director of the Clinical Research Office. Dr. Beg conducts trials for new cancer treatments and is Principal Investigator for the Simmons Comprehensive Cancer Center Experimental Therapeutics Clinical Trials Network (ETCTN) Clinical Trial Network National Cancer Institute (NCI) UM1 grant.
He completed the Leadership Development Program of the American Society of Clinical Oncology where he serves on the Cancer Communications Committee and is on the Editorial Board of ASCO Daily News. He leads the Pancreatic-Hepatobiliary Cancers working group of the ECOG-ACRIN Cancer Research Group’s Gastrointestinal Cancer Core Committee. He is also a member of the National Cancer Institute (NCI) GI Cancer Steering Committee’s Pancreatic Cancer task force. Additionally, he is leading multiple trials on drug combinations in our labs at UT Southwestern.
Prior to joining joined UT Southwestern in 2011, Dr. Beg attended medical school at Aga Khan University in Karachi, Pakistan, where he graduated with honors. He completed his residency in internal medicine and a fellowship in hematology/oncology at the University of Cincinnati.
Dr. Beg is board certified in hematology and medical oncology, and he is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.
His research has been featured in national and international cancer meetings, and he has published articles in many peer-reviewed medical publications including Journal of Clinical Oncology, JAMA Oncology, Clinical Cancer Research and Cancer Cell. Dr. Beg is often invited to give lectures on pancreatic cancer treatments and health information technology, and he is a reviewer for multiple oncology journals.
Dr. Beg has been included in D Magazine's Best Doctors list between 2016 and 2018, and was named a Texas Monthly Super Doctor from 2013 to 2018.
When he’s not working, Dr. Beg spends quality time with his wife and their two children. He also enjoys traveling and exploring the outdoors. He is very interested in understanding how to use electronic communication tools such as social media to better communicate scientific findings.
Meet Dr. Beg
Medical Oncologist and GI Cancer Specialist
In the fight against gastrointestinal cancers, Muhammad Shaalan Beg, M.D., is leading the charge.
"I spend a lot of time trying to understand what my patients' needs and expectations are, and what they want me to help them achieve. Is it to continue being able to work their current job, keep playing the piano, or attend a grandchild's graduation party? I need to understand where my patient is coming from."
As a medical oncologist at UT Southwestern Medical Center’s Simmons Cancer Center, Dr. Beg treats patients with pancreatic, liver, colorectal, and stomach cancer, as well as rare cancers such as neuroendocrine tumors and gastrointestinal stromal tumors (GIST). He is also Associate Professor of Hematology and Medical Oncology and is co-Leader of the Gastrointestinal Cancer Multidisciplinary team.
Dr. Beg is very active in clinical research including leading clinical trials at the Simmons Cancer Center, where he is bringing promising basic science discoveries from the lab to the clinic to better care for his patients.
He believes that GI cancers are best treated by a group of doctors. GI cancer patients are a very special and diverse group with specific needs, so Dr. Beg spends a lot of time getting to know his patients to assess their needs and expectations for cancer care. He believes in offering the best, personalized care available, which includes cutting-edge medical care, clinical trials, and innovations in surgery.
“We need to provide patients with more opportunities, and the best way to do that is through clinical trials,” Dr. Beg says. “My goal is to bring ideas from the lab and see how we can apply that to the clinic. We always think of clinical trials as something we are investing our time and money in, but if it’s not helping the patient, it’s not really a benefit at all.”
- American Society of Clinical Oncology (2008)
- American Association for Cancer Research (2011)
- Resident Teacher Award 2008, University of Cincinnati
- Leadership Development Program - American Society of Clinical Oncology 2018-2019
- Leadership Emerging in Academic Departments (LEAD) Program - UT Southwestern Medical Center 2016
- Cancer Communications Committee - American Society of Clinical Oncology 2018-2021
- Pancreatic Cancer Task Force, GI Cancer Steering Committee, NCI 2017-2021
- Chair, Pancreatic-Hepatobiliary Working Group, GI Core Committee ECOG/ACRIN 2017-2021
Phase 1 study of ARQ 761, a ß-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA British journal of cancer 2018 Oct 119 8 928-936
Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications.
Hosein AN, Beg MS Current oncology reports 2018 May 20 7 56
Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers.
Beg MS, Meyer J Journal of gastrointestinal oncology 2018 Feb 9 1 225-230
Approach and management of checkpoint inhibitor-related immune hepatitis.
Sanjeevaiah A, Kerr T, Beg MS Journal of gastrointestinal oncology 2018 Feb 9 1 220-224
Characteristics and impact of the most-cited palliative oncology studies from 1995 to 2016.
Eule C, Bhulani N, Paulk E, Rhodes R, Beg MS BMC cancer 2018 Dec 18 1 1281
The NQO1 bioactivatable drug, ß-Lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, Beg MS, Burgess SC, DeBerardinis RJ, Boothman DA, Merritt ME The Journal of biological chemistry 2017 Sep
Pasireotide for the Treatment of Refractory Hypoglycemia from Malignant Insulinoma.
Hendren NS, Panach K, Brown TJ, Peng L, Beg MS, Weissler J, Mirfakhraee S Clinical endocrinology 2017 Oct
Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus.
Arora N, Gupta A, Zhu H, Christie A, Meyer JJ, Khan SA, Beg MS Journal of the National Comprehensive Cancer Network : JNCCN 2017 Aug 15 8 998-1004
Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis.
Gerber DE, Beg MS, Duncan T, Gill M, Craddock Lee SJ Oncology nursing forum 2017 03 44 2 165-170
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.
Beg MS, Azad NS, Patel SP, Torrealba J, Mavroukakis S, Beatson MA, Wang XP, Arlen PM, Morse MA Cancer chemotherapy and pharmacology 2016 Jul
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS Investigational new drugs 2016 Dec
A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study.
Beg MS, Saleem S, Turer A, Ayers C, de Lemos JA, Khera A, Scherer PE, Lakoski SG Journal of the National Comprehensive Cancer Network : JNCCN 2015 Jul 13 7 873-8
A Variant in PNPLA3 Associated with Fibrosis Progression but not Hepatocellular Carcinoma in Patients With HCV Infection.
Ali M, Yopp A, Gopal P, Beg MS, Zhu H, Lee W, Singal AG Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015 Aug
Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer.
Beg MS, Dwivedi AK, Ahmad SA, Ali S, Olowokure O PloS one 2014 9 5 e98511
Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome.
Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, Pedrosa I, Khatri G, Yakoo T, Meyer JJ, Shaw J, Marrero JA, Singal AG Annals of surgical oncology 2013 Dec
Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States.
Tan D, Yopp A, Beg MS, Gopal P, Singal AG Alimentary pharmacology & therapeutics 2013 Aug
Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.
Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF Leukemia research 2010 Jan 34 1 59-62
A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma.
Meyer J, Arriaga Y, Anandam J, Karri S, Syed S, Verma U, Abdelnaby A, Raja G, Dong Y, Beg MS, Balch G American journal of clinical oncology 2018 Oct 41 10 972-976
Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey.
Gupta A, Das A, Tariq R, Bhulani N, Premnath N, Solanky D, Frank RD, Johnson D, Khanna S, Beg MS Journal of the National Comprehensive Cancer Network : JNCCN 2018 Mar 16 3 286-292
An Analysis of Individual Body Fat Depots and Risk of Developing Cancer: Insights From the Dallas Heart Study.
Gupta A, Pandey A, Ayers C, Beg MS, Lakoski SG, Vega GL, Grundy SM, Johnson DH, Neeland IJ Mayo Clinic proceedings 2017 Mar
Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI.
Yokoo T, Clark HR, Pedrosa I, Yuan Q, Dimitrov I, Zhang Y, Lingvay I, Beg MS, Bobulescu IA Journal of magnetic resonance imaging : JMRI 2016 Mar
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA Cancer cell 2016 Dec 30 6 940-952
Predictive factors for early aspiration in liver abscess.
Khan R, Hamid S, Abid S, Jafri W, Abbas Z, Islam M, Shah H, Beg S, World journal of gastroenterology 2008 Apr 14 13 2089-93
The Future of Wearable Technologies and Remote Monitoring in Health Care.
Liao Y, Thompson C, Peterson S, Mandrola J, Beg MS, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019 Jan 39 115-121
NQO1-dependent, tumor-selective radiosensitization of non-small cell lung cancers.
Motea EA, Huang X, Singh N, Kilgore JA, Williams NS, Xie XJ, Gerber DE, Beg M, Bey EA, Boothman DA Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Jan
Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer.
Bhulani N, Gupta A, Gao A, Li J, Guenther C, Ahn C, Paulk E, Houck S, Beg MS Journal of gastrointestinal oncology 2018 Jun 9 3 495-502
Modulators of Redox Metabolism in Head and Neck Cancer.
Chen X, Mims J, Huang X, Singh N, Motea E, Planchon SM, Beg M, Tsang AW, Porosnicu M, Kemp ML, Boothman DA, Furdui CM Antioxidants & redox signaling 2018 Dec 29 16 1660-1690
Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients.
Kobayashi M, Chung JS, Beg M, Arriaga Y, Verma UN, Courtney K, Mansour JC, Haley B, Khan SA, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD, Ariizumi K Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Jul
Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis.
Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, Singh S American journal of clinical oncology 2017 May
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC Targeted oncology 2017 Mar
Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab.
Brown TJ, Sher DJ, Nedzi LA, Hughes RS, Beg MS, Mull J, Sarode VR, Khan SA Head & neck 2017 Feb
Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017.
Sanford NN, Lam MB, Butler SS, Ahn C, Beg MS, Aizer AA, Mahal BA, JAMA oncology 2019 May e191973
Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis.
Gupta A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, Hughes R, Singh S, Johnson DH Lung cancer (Amsterdam, Netherlands) 2016 Dec 102 49-59
The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis.
Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK The American journal of gastroenterology 2014 Jan
Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Anal Cancer.
Hodges JC, Beg MS, Das P, Meyer J International journal of radiation oncology, biology, physics 2014 Apr
Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis.
Gupta A, Tariq R, Frank RD, Jean GW, Beg MS, Pardi DS, Johnson DH, Khanna S Journal of the National Comprehensive Cancer Network : JNCCN 2017 Apr 15 4 466-472
Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection?
Stern JH, Arriaga Y, Gupta A, Verma U, Karri S, Syed S, Khosama L, Mansour J, Meyer J, Scherer PE, Beg MS Pancreas 2019 Jan 48 1 e1-e3
Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer.
Singh J, Moore W, Fattah F, Jiang X, Zheng J, Kurian P, Beg MS, Khan SA Head & neck 2019 Jan 41 1 E11-E16
Outcome of esophageal carcinoma in the veteran affairs population: a comparative analysis from the Veteran Affairs Central Cancer Registry.
Beg MS, Navaneethan U, Atiq M, Komrokji R, Safa M American journal of clinical oncology 2009 Jun 32 3 286-90
Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data.
Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM Clinical lymphoma, myeloma & leukemia 2011 Jun 11 3 257-60
Oxaliplatin-induced immune mediated thrombocytopenia.
Beg MS, Komrokji RS, Ahmed K, Safa MM Cancer chemotherapy and pharmacology 2008 Oct 62 5 925-7
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Dec 38 36 4317-4345
Ascites, or Fluid in the Belly, in Patients With Cancer.
Gupta A, Sedhom R, Beg MS, JAMA oncology 2020 02 6 2 308
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS, Annals of surgery 2020 Jul
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS, British journal of cancer 2020 May 122 11 1630-1637
Targeting TAM to Tame Pancreatic Cancer.
von Itzstein MS, Burke MC, Brekken RA, Aguilera TA, Zeh HJ, Beg MS, Targeted oncology 2020 Sep
- Phase 1 study of ARQ 761, a ß-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
- Cancer of Pancreas, Liver, and Bile Duct
- Digital Health
- Experimental Therapeutics
- Clinical Informatics
- Early Phase Drug Development, Phase I/II Clinical Trials
- Cancers of the Gastrointestinal Tract
- Decentralized Clinical Trials
- Medical Treatment of Pancreatic Cancer
- Pancreatic Cancer
- Liver Cancer
- Gallbladder/Bile Duct (Cholangiocarcinoma) Cancer
Q&A by Dr. Beg
Articles by Dr. Beg
Showing 1 locations